MetaCap

Amarin (AMRN) vs Kamada (KMDA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Kamada (KMDA) has outperformed Amarin (AMRN) over the past year, gaining 14.7% versus a loss of 35.5%. Over five years, KMDA leads with a +22.7% price change compared with -85.5% for AMRN. Kamada is the larger company by market cap ($446.8 million vs $444.4 million), about 1.0 times the size.

On valuation, Amarin trades at a lower forward P/E (10.8x vs 13.3x for Kamada). Kamada pays a dividend yielding 7.24%, while Amarin does not currently pay one. Kamada converts more of its revenue into profit, with a net margin of 11.2% versus -18.2%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AMRN-35.47%KMDA+14.67%
+42%+1%-39%
Nov 21, 20251 yearNov 20, 2026
AMRN-86.45%KMDA+38.21%
+66%-16%-97%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AMRN versus KMDA key metrics
MetricAMRNKMDA
Share price$10.57$7.74
Market cap$444.39M$446.85M
1-day change-6.13%-1.15%
YTD return-24.28%+9.63%
1-year return-35.47%+14.67%
5-year return-85.48%+22.66%
P/E ratio (TTM)—20.37
Forward P/E10.7913.34
EPS (TTM)$-0.80$0.38
Dividend yield0.00%7.24%
Annual dividend$0.00$0.56
Revenue (latest FY)$213.65M$180.46M
Revenue growth (YoY)-6.55%+12.12%
Net income (latest FY)$-38.80M$20.20M
Gross margin56.57%42.34%
Operating margin-23.48%14.54%
Net margin-18.16%11.19%
52-week high$17.31$9.35
52-week low$10.56$6.63
Distance from 52-week high-38.94%-17.22%
Analyst consensusnonestrong_buy
Avg. price target upside+22.99%+77.65%
Average volume79.50K121.87K
Shares outstanding42.04M57.73M
Employees80462
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • KMDA has outperformed AMRN by 50.1 percentage points over the past year.
  • Kamada offers a meaningfully higher dividend yield (7.24% vs 0.00%).
  • Kamada is more profitable, keeping 11.2 cents of every revenue dollar as net income versus -18.2 cents for Amarin.
  • Kamada grew revenue faster in its latest fiscal year (+12.12% vs -6.55%).

About Amarin

AMRN stock →

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.

Health Care · Biotechnology: Pharmaceutical Preparations · 80 employees

About Kamada

KMDA stock →

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics.

Health Care · Biotechnology: Pharmaceutical Preparations · 462 employees

AMRN vs KMDA FAQ

Which is bigger, Amarin or Kamada?

Kamada (KMDA) is larger, with a market capitalization of $446.85M compared with $444.39M for Amarin (AMRN).

Which stock has performed better over the past year, AMRN or KMDA?

KMDA returned +14.67% over the past 12 months, compared with -35.47% for AMRN (price return, excluding dividends). Past performance does not predict future results.

Which pays a higher dividend, Amarin or Kamada?

Kamada pays a dividend yielding 7.24%, while Amarin does not currently pay a regular dividend.

Are Amarin and Kamada in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons